middle.news
Firebrick Pharma Validates Nasodine’s Cold Relief in Peer-Reviewed Phase 3 Study
8:57am on Tuesday 10th of June, 2025 AEST
•
Healthcare
Read Story
Firebrick Pharma Validates Nasodine’s Cold Relief in Peer-Reviewed Phase 3 Study
8:57am on Tuesday 10th of June, 2025 AEST
Key Points
Phase 3 trial results published in high-impact journal
Nasodine reduces cold severity by 40% if used within 24 hours
Treatment shown to be safe and well tolerated
Regulatory review and appeals delayed publication
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
FRE
OPEN ARTICLE